Heart Failure Reviews最新文献_第4页

SEISMIC-HF 1: key findings from AHA24 and implications for remote cardiac monitoring. SEISMIC-HF 1: AHA24的主要发现及其对远程心脏监测的意义。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2025-04-23 DOI: 10.1007/s10741-025-10514-1

Baljash Cheema, Anjan Tibrewala

{"title":"SEISMIC-HF 1: key findings from AHA24 and implications for remote cardiac monitoring.","authors":"Baljash Cheema, Anjan Tibrewala","doi":"10.1007/s10741-025-10514-1","DOIUrl":"https://doi.org/10.1007/s10741-025-10514-1","url":null,"abstract":"While there is continued progress in developing therapies for patients with heart failure, the condition results in significant morbidity and a sizeable economic impact on our society. Recent advances in wearable sensors combined with machine learning algorithms give hope that heart failure can be better managed remotely and allow for improved clinical outcomes. This is a focused review of the key findings of the SEISMocardiogram In Cardiovascular Monitoring for Heart Failure I (SEISMIC-HF 1) study, presented at the American Heart Association's Scientific Sessions 2024 in Chicago, Illinois. This study showcased the ability of a machine learning algorithm to estimate pulmonary capillary wedge pressure in patients with heart failure with reduced ejection fraction, utilizing seismocardiography, photoplethysmography, and electrocardiography signals obtained non-invasively through a wearable sensor patch (CardioTag) for model input. The authors showed a significant correlation between model-predicted pulmonary capillary wedge pressure and the gold standard pressure measurement obtained from right heart catheterization. Future investigations should assess the implementation of this technology as a part of a treatment strategy for outpatient heart failure care and explore its performance in additional study populations including those with heart failure with preserved ejection fraction and in patients outside of the clinical environment.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143997488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Radiofrequency-based wearable sensor patch in heart failure management: a focused review. 基于射频的可穿戴传感器贴片在心力衰竭管理中的应用综述。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2025-04-09 DOI: 10.1007/s10741-025-10511-4

Phuuwadith Wattanachayakul, Veraprapas Kittipibul, Marat Fudim

{"title":"Radiofrequency-based wearable sensor patch in heart failure management: a focused review.","authors":"Phuuwadith Wattanachayakul, Veraprapas Kittipibul, Marat Fudim","doi":"10.1007/s10741-025-10511-4","DOIUrl":"https://doi.org/10.1007/s10741-025-10511-4","url":null,"abstract":"ZOLL Heart Failure Management System (ZOLL HFMS) is a non-invasive, remote monitoring device that employs radiofrequency signals transmitted through an adhesive patch embedded with integrated sensors to evaluate lung fluid levels. By analyzing trends in lung fluid status and related parameters, ZOLL HFMS may facilitate the early detection of heart failure (HF) decompensation and enable timely interventions. Insights from the recent BMAD trial (Impact of heart failure management using thoracic fluid monitoring from a novel wearable sensor: Results of the Benefits of Microcor [µCor™] in Ambulatory Heart Failure) highlight its promise in those with recent HF hospitalization, demonstrating a reduction in time to first HF readmission and improvement in quality of life. In this review, we summarize data on the ZOLL HFMS, with a focus on its lung fluid analysis mechanism for early HF decompensation detection and the accuracy of its measurements compared to other modalities. Then, we examine key outcomes from the recent BMAD trial, highlighting their clinical relevance and identifying gaps that warrant further investigation in future clinical trials. Lastly, we outline potential directions for integrating this technology into routine HF management.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144000558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Outpatient worsening heart failure: innovative decongestion strategies and health equity implications. 门诊恶化心力衰竭：创新的去充血策略和健康公平的影响。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2025-04-05 DOI: 10.1007/s10741-025-10509-y

Rami Halaseh, Grace K Sun, Ankeet S Bhatt, Alex J Chang, Jana Svetlichnaya, Sirtaz Adatya, Marat Fudim, Stephen J Greene, Daniel R Bensimhon, Eric D Adler, Tamas Alexy, Jan Biegus, Andrew J Sauer, Peter S Pang, Sean P Collins, Ambarish Pandey, Javed Butler, Andrew P Ambrosy

{"title":"Outpatient worsening heart failure: innovative decongestion strategies and health equity implications.","authors":"Rami Halaseh, Grace K Sun, Ankeet S Bhatt, Alex J Chang, Jana Svetlichnaya, Sirtaz Adatya, Marat Fudim, Stephen J Greene, Daniel R Bensimhon, Eric D Adler, Tamas Alexy, Jan Biegus, Andrew J Sauer, Peter S Pang, Sean P Collins, Ambarish Pandey, Javed Butler, Andrew P Ambrosy","doi":"10.1007/s10741-025-10509-y","DOIUrl":"https://doi.org/10.1007/s10741-025-10509-y","url":null,"abstract":"Worsening heart failure (WHF) is a major clinical and economic challenge, contributing to high rates of hospitalization and significant healthcare costs. While WHF has traditionally been managed through hospitalization, recent approaches are shifting toward outpatient care to maximize patient time spent at home and optimize allocation of hospital resources. Emerging treatments like subcutaneous furosemide and intranasal bumetanide offer promising alternatives for safe, well-tolerated, and effective diuresis outside the hospital. However, these novel strategies face several challenges, including the need for clinician/staff training, patient education, logistical difficulties, and a lack of evidence in diverse populations. To ensure equitable management, it is also essential to address healthcare disparities, particularly in socioeconomically disadvantaged and rural populations. While these new treatments have the potential to improve care delivery, additional research is necessary to assess their comparative effectiveness and overcome current limitations fully.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143788211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Device-based therapies for heart failure with preserved ejection fraction. 基于设备的射血分数保留型心力衰竭疗法。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2025-04-04 DOI: 10.1007/s10741-025-10510-5

Ryan Kim, Veraprapas Kittipibul, Sapna Bhatt, Marat Fudim

引用次数: 0

Semaglutide in heart failure and atherosclerotic cardiovascular disease: the current state-of-the-art. 塞马鲁肽在心力衰竭和动脉粥样硬化性心血管疾病中的应用：最新进展。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2025-03-31 DOI: 10.1007/s10741-025-10506-1

Nikolaos Theodorakis, Magdalini Kreouzi, Maria Nikolaou

{"title":"Semaglutide in heart failure and atherosclerotic cardiovascular disease: the current state-of-the-art.","authors":"Nikolaos Theodorakis, Magdalini Kreouzi, Maria Nikolaou","doi":"10.1007/s10741-025-10506-1","DOIUrl":"https://doi.org/10.1007/s10741-025-10506-1","url":null,"abstract":"Cardiovascular disease mortality rates, which had steadily declined over decades, are now plateauing or reversing due to the global rise in type 2 diabetes mellitus (T2DM) and obesity. These cardiometabolic conditions contribute significantly to atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), and chronic kidney disease. Among emerging pharmacological treatments, glucagon-like peptide-1 receptor agonists, particularly semaglutide, have shown benefits beyond diabetes and obesity management, including cardioprotective and renoprotective effects. This state-of-the-art review comprehensively analyzes current evidence from clinical trials, identifies critical insights, and outlines research directions regarding semaglutide use in HF, ASCVD, and diabetic nephropathy. In ASCVD, semaglutide has demonstrated significant reductions in major adverse cardiovascular events, supported by findings from meta-analyses of trials in patients with T2DM and the SELECT trial for patients without T2DM. In a prespecified analysis of the SELECT trial, semaglutide demonstrated significant reductions in cardiovascular mortality and HF hospitalizations for patients with HF and ASCVD. In HF with preserved ejection fraction and mildly reduced ejection fraction, semaglutide improved symptoms, physical function, natriuretic peptide levels, echocardiographic parameters, and HF hospitalizations, as shown in the STEP-HFpEF program and a pooled analysis of trials. Furthermore, evidence from the FLOW trial underscores semaglutide's renal and cardiovascular benefits in diabetic nephropathy, irrespective of body mass index. While these findings suggest semaglutide's efficacy in cardiorenal diseases, gaps in evidence remain, including the need for event-driven trials in HF populations without ASCVD and irrespective of obesity. Future research should address these gaps, which could potentially update guideline recommendations.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chronic venous insufficiency in heart failure: exploring a reciprocal influence on cardiovascular health. 心力衰竭的慢性静脉功能不全：探索对心血管健康的相互影响。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2025-03-29 DOI: 10.1007/s10741-025-10508-z

Vito A Damay, Ignatius Ivan, Victor Manuel Canata Benitez

{"title":"Chronic venous insufficiency in heart failure: exploring a reciprocal influence on cardiovascular health.","authors":"Vito A Damay, Ignatius Ivan, Victor Manuel Canata Benitez","doi":"10.1007/s10741-025-10508-z","DOIUrl":"https://doi.org/10.1007/s10741-025-10508-z","url":null,"abstract":"Chronic venous insufficiency (CVI) is a prevalent disorder, arising from venous valve incompetence and vein wall weakness, which impairs blood return and leads to venous stasis and hypertension in the lower extremities. This condition, affecting up to 40% of older adults, has been primarily considered a peripheral issue. However, growing evidence indicates its systemic impacts, notably its contribution to cardiovascular dysfunction and heart failure (HF). CVI exacerbates central venous pressure and cardiac preload, placing strain on the right heart and predisposing at-risk patients to HF. Moreover, a feedback loop exists where HF worsens CVI through increased venous stasis and fluid overload, highlighting a complex bidirectional relationship. Emerging research reveals that CVI-driven inflammation and endothelial dysfunction may accelerate adverse cardiac dysfunction. This review provides a comprehensive analysis of CVI's systemic effects, emphasizing the need for integrated cardiovascular and venous management strategies to address the reciprocal influences of CVI and HF. Such an approach could reduce disease progression and enhance outcomes for affected patients.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction to: Worsening heart failure: progress, pitfalls, and perspectives. 更正：恶化的心力衰竭：进展、陷阱和前景。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2025-03-28 DOI: 10.1007/s10741-025-10507-0

Cândida Fonseca, Rui Baptista, Fátima Franco, Brenda Moura, Joana Pimenta, Pedro Moraes Sarmento, José Silva Cardoso, Dulce Brito

引用次数: 0

Electronic health record nudges to optimize guideline-directed medical therapy for heart failure. 电子健康记录推动优化心力衰竭的指导医学治疗。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2025-03-19 DOI: 10.1007/s10741-025-10503-4

Michael A Fuery, Katherine A Clark, Nikhil V Sikand, Sara R Tabtabai, Sounok Sen, F Perry Wilson, Nihar R Desai, Tariq Ahmad, Marc D Samsky

{"title":"Electronic health record nudges to optimize guideline-directed medical therapy for heart failure.","authors":"Michael A Fuery, Katherine A Clark, Nikhil V Sikand, Sara R Tabtabai, Sounok Sen, F Perry Wilson, Nihar R Desai, Tariq Ahmad, Marc D Samsky","doi":"10.1007/s10741-025-10503-4","DOIUrl":"https://doi.org/10.1007/s10741-025-10503-4","url":null,"abstract":"Electronic health record (EHR) alert nudges are emerging as a valuable tool for improving heart failure (HF) management, particularly by enhancing the use of guideline-directed medical therapy (GDMT). These nudges, integrated as clinical decision support (CDS) tools within EHR systems, provide real-time, evidence-based prompts that assist clinicians in making informed treatment decisions at critical moments in patient care. Studies have shown that targeted alerts can improve GDMT adherence and outcomes. Designing effective nudges requires aligning alert content, timing, and format with clinician workflows to reduce alert fatigue and enhance usability. Furthermore, involving clinicians in the design process helps ensure alerts are relevant, context-sensitive, and integrated smoothly into practice. EHR nudges present an innovative approach to bridging quality gaps in HF care by encouraging timely interventions and adherence to best practices, but their efficacy depends on thoughtful implementation. Future research is needed to refine alert strategies, optimize their impact on clinical outcomes, and explore their role across diverse healthcare settings, ultimately advancing the potential of EHR nudges to improve HF care quality.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143663349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Heart and brain interactions in heart failure: pathophysiological mechanisms and clinical perspectives. 心力衰竭的心脏和大脑相互作用：病理生理机制和临床观点。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2025-03-18 DOI: 10.1007/s10741-025-10505-2

Sotiria Liori, Angelos Arfaras-Melainis, Vasiliki Bistola, John Parissis

{"title":"Heart and brain interactions in heart failure: pathophysiological mechanisms and clinical perspectives.","authors":"Sotiria Liori, Angelos Arfaras-Melainis, Vasiliki Bistola, John Parissis","doi":"10.1007/s10741-025-10505-2","DOIUrl":"https://doi.org/10.1007/s10741-025-10505-2","url":null,"abstract":"Heart failure (HF) is a complex and debilitating syndrome that affects millions of people worldwide. In addition to the syndrome-related functional limitations, such as exercise intolerance and dyspnea, patients frequently suffer from various comorbidities. Neuropsychiatric conditions, including autonomic dysfunction, cognitive impairment, and depression, are important albeit underrecognized comorbidities in HF. Autonomic dysfunction, which is expressed as sympathetic predominance and decreased parasympathetic tone, is a key contributor to HF progression. Depression and cognitive impairment are highly prevalent in HF patients, affecting adherence to medical treatment and increasing morbidity and mortality risk. Stress cardiomyopathy, a usually reversible form of left ventricular dysfunction triggered by emotional or physical stress, is another clinical manifestation of the interplay between the heart and the brain. Early recognition and management of these comorbidities in HF patients are crucial for improving outcomes. This narrative review provides an overview of the pathophysiological mechanisms linking HF and brain disorders and discusses clinical perspectives of heart-brain interactions in the context of HF.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143648402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Leptin and heart failure: the chicken or the egg? 瘦素和心力衰竭：是先有鸡还是先有蛋？

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2025-03-17 DOI: 10.1007/s10741-025-10501-6

Nikolaos Theodorakis, Maria Nikolaou

{"title":"Leptin and heart failure: the chicken or the egg?","authors":"Nikolaos Theodorakis, Maria Nikolaou","doi":"10.1007/s10741-025-10501-6","DOIUrl":"https://doi.org/10.1007/s10741-025-10501-6","url":null,"abstract":"Leptin plays a dual role in heart failure (HF), acting as either a primary driver or a secondary phenomenon depending on the HF subtype. In HF with preserved ejection fraction (HFpEF), chronic hyperleptinemia is a primary mediator of disease initiation and progression, closely linked to obesity and metabolic dysfunction. Elevated leptin levels promote systemic inflammation, sympathetic nervous system activation, arterial stiffness, myocardial hypertrophy, fibrosis, and sodium retention, culminating in diastolic dysfunction and elevated ventricular filling pressures. Conversely, in HF with reduced ejection fraction (HFrEF), elevated leptin levels arise as a secondary response to myocardial dysfunction, systemic inflammation, and tissue hypoperfusion. Here, leptin exacerbates cardiac dysfunction by amplifying neurohormonal activation, inflammation, and cardiac remodeling. Understanding these distinct roles has potential therapeutic implications. In HFpEF, interventions such as weight loss, glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors, and mineralocorticoid receptor antagonists can improve symptoms and prognosis, partly by mitigating chronic hyperleptinemia. Furthermore, leptin-specific therapies should be investigated in clinical trials as potential approach in managing cardiometabolic HFpEF. In HFrEF, management focuses on guideline-directed therapies targeting neurohormonal activation-the key mechanism driving disease progression. However, future research should explore whether modulating leptin signaling could provide additional benefits translated in hard clinical endpoints. By framing leptin as the initiator (\"chicken\") in HFpEF and a consequence (\"egg\") in HFrEF, this manuscript highlights the need for individualized, integrated treatment strategies. Addressing both metabolic and cardiovascular components could potentially further improve patient outcomes and quality of life.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143648403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0